|
Vinorelbine
resources
|
|
|
|
|
|
DRUG INFO
Vinorelbine
Drug Name:
Vinorelbine
Indication: For the treatment of non-small-cell lung carcinoma
Pharmacology: Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Mechanism Of Action: The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Drug Category: Radiation-Sensitizing Agents; Antineoplastic Agents; ATC:L01CA04
Brand Names/Synonyms: KW 2307; Kw 2307 Base; Navelbine; Navelbine Base; VINORELBINE; Vinorelbin; Vinorelbina [Spanish]; Vinorelbine Bitartrate; Vinorelbine Ditartarate; Vinorelbine Ditartrate; Vinorelbine Tartrate; Vinorelbinum [Latin]
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions:
DrugBank: Interactions for Vinorelbine
Interactions for Vinorelbine:
Acute pulmonary reactions have been reported with NAVELBINE and other anticancer vinca alkaloids used
in conjunction with mitomycin. Although the pharmacokinetics of vinorelbine are not influenced by the concurrent
administration of cisplatin, the incidence of granulocytopenia with NAVELBINE used in combination with cisplatin is
significantly higher than with single-agent NAVELBINE. Patients who receive NAVELBINE and paclitaxel, either
concomitantly or sequentially, should be monitored for signs and symptoms of neuropathy. Administration of NAVELBINE
to patients with prior or concomitant radiation therapy may result in radiosensitizing effects.
Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by
hepatic cytochrome P450 isoenzymes in the CYP3A subfamily, or in patients with hepatic dysfunction. Concurrent
administration of vinorelbine tartrate with an inhibitor of this metabolic pathway may cause an earlier onset and/or
an increased severity of side effects.
Chemical IUPAC Name: Not Available
Chemical Formula: C45H54N4O8
Half Life: 27.7-43.6 hours
Drug Type: Approved Drug
# Accession No: APRD00101
CAS Registry Number: 71486-22-1
|
|
|
|
|
|
Vinorelbine News
(When available)
Chemioterapia personalizzata in base ad effetti collaterali Jan 2, 2006
Pillole.org, ...sono stati considerati 1265 pazienti in trattamento chemioterapico (vinorelbina, gemcitabinea, gemcitabina e vinorelbina, cisplatino e vinorelbina, o ...
|
|
|
